Sucampo Pharmaceuticals Announces Issuance of New Patent for VTS-270 ROCKVILLE, Md., June 13, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the U.S. Patent and Trademark Office...

Sucampo Reports First Quarter 2017 Financial Results Continued Revenue Growth Recent Vtesse Acquisition Bolsters Pipeline Company Reiterates 2017 Guidance Company to Host Conference Call Today at 8:30 a.m. EDT ROCKVILLE, Md., May 03, 2017 (GLOBE...

New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1 ROCKVILLE, Md., April 18, 2017 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (NASDAQ:SCMP), a global biopharmaceutical company, today announced the publication of a new study in an...

Sucampo Acquires Vtesse Inc. Transaction Valued at $200 Million Upfront Diversifies Pipeline with Late Stage Program in Niemann-Pick Disease Type C1 (NPC-1) Increases Company Focus on Specialized Diseases with High Unmet Need ...